AG 1295
博飞美科提供的所有产品仅用于科研等非医疗用途，非药品不可食用，不可用于人体或动物的临床诊断和治疗,我们不为个人提供产品及服务。如您需要产品COA等资料，可至下方“质量控制”中下载
PA06883
PERFEMIKER
71897-07-9
C16H14N2
234.30
*注意事项:下单时请联系销售核实产品价格及货期，避免后续产生不便，感谢支持!
| 产品名称： |
AG 1295,98% |
| 中文别名： |
5,5'-二溴-2,2'-联吡啶;6,7-二甲基-2-苯基喹噁啉;酪氨酸磷酸化抑制剂AG1295;6,7-二甲基-2-苯基喹喔啉 |
| 英文名称： |
AG 1295 |
| 英文别名： |
ag 1295;AG-1295;6,7-dimethyl-2-phenylquinoxaline;2-phenyl-6,7-dimethylquinoxaline;6,7-Dimethyl-2-phenyl-chinoxalin;6,7-dimethyl-2-phenyl-quinoxaline;F1284-0835;TYRPHOSTIN AG 1295;AG 1295;6,7-DIMETHYL-2-PHENYLQUINOXALINE;TYROPHOSTIN AG1295;AG 1295 PLATELET-DERIVED GROW;TYRPHOSTIN AG 1295, 99+%;Quinoxaline, 6,7-dimethyl-2-phenyl-;AG-1295
(NSC 380341;HMS1427I07;NCGC00163373-01;SR-01000409995;FQNCLVJEQCJWSU-UHFFFAOYSA-N;cid_2048;HMS3229M19;HMS2879L07;MLS001194710;BRD-K57926513-001-03-7;Tyrphostin AG1295;WCA89707;IFLab1_005463;CHEBI:94668;(5-Bromo-2-pyrimidinyl)propanedioic acid diethyl ester;IDI1_010866;ag1295;D95572;AG 1295 - CAS 71897-07-9;HY-101957;HMS1369L14;CCG-15824;HSCI1_000140;CS-0022014;BiomolKI2_000029;SR-01000409995-1;FWH2FYS649;6,7-Dimethyl-2-phenyl-quinoxaline;Tyrphostin AG-1295;AS-76528;ChemDiv2_000256;BMK1-C7;SCHEMBL925674;HMS3428I13;NCGC00163373-02;EN300-68256;BRD-K57926513-001-02-9;SMR000554870;2-Phenyl-6,7-dimethylquinoxaline;GTPL5914;6,7-Dimethyl-2-phenylquinoxaline;BDBM33408;UPCMLD0ENAT5762488:001;6,7-Dimethyl-2-phenylquinoxaline #;Q27074334;NSC380341;DTXSID10274351;NSC-380341;BiomolKI_000019;CHEMBL7724;Z234853442;71897-07-9;AKOS001326347 |
| 品牌： |
PERFEMIKER |
| CAS号： |
71897-07-9 |
| 分子式： |
C16H14N2 |
| 分子量： |
234.30 |
| 纯度： |
98% |
| 详细描述： |
博飞美科的AG 1295,98%为抑制剂,产品稳定,定制速度快,极大地方便了广大科研客户的使用需求。产品包装为5mg。查询关键词:抑制剂，71897-07-9，AG 1295,98%，AG 1295，博飞美科，Perfemiker，上海，厂家直销。 |
沪公网安备31011402010658号 
C(%5bH%5d)(%5bH%5d)%5bC%40%40%5d(C(%5bH%5d)(%5bH%5d)%5bH%5d)(%5bC%40%5d(%5bH%5d)(%5bC%40%5d(%5bH%5d)(C(%5bH%5d)(%5bH%5d)%5bH%5d)O1)OC(C(%5bH%5d)(%5bH%5d)%5bH%5d)%3dO)O%5bH%5d)%5bC%40%40%5d1(%5bH%5d)%5bC%40%40%5d(%5bH%5d)(%5bC%40%40%5d(%5bH%5d)(C(%5bH%5d)(%5bH%5d)%5bH%5d)O%5bC%40%5d(%5bH%5d)(C1(%5bH%5d)%5bH%5d)O%5bC%40%40%5d1(%5bH%5d)%5bC%40%40%5d(%5bH%5d)(%5bC%40%40%5d(%5bH%5d)(C(%5bH%5d)(%5bH%5d)%5bH%5d)O%5bC%40%5d(%5bH%5d)(C1(%5bH%5d)%5bH%5d)O%5bC%40%5d1(%5bH%5d)C(C2C(%3dC3C(%3dC(C(%5bH%5d)(%5bH%5d)%5bH%5d)C(%3dC(%5bH%5d)C3%3dC(%5bH%5d)C%3d2C(%5bH%5d)(%5bH%5d)%5bC%40%40%5d1(%5bH%5d)%5bC%40%40%5d(%5bH%5d)(C(%5bC%40%5d(%5bH%5d)(%5bC%40%40%5d(%5bH%5d)(C(%5bH%5d)(%5bH%5d)%5bH%5d)O%5bH%5d)O%5bH%5d)%3dO)OC(%5bH%5d)(%5bH%5d)%5bH%5d)O%5bC%40%40%5d1(%5bH%5d)C(%5bH%5d)(%5bH%5d)%5bC%40%5d(%5bH%5d)(%5bC%40%5d(%5bH%5d)(%5bC%40%40%5d(%5bH%5d)(C(%5bH%5d)(%5bH%5d)%5bH%5d)O1)OC(C(%5bH%5d)(%5bH%5d)%5bH%5d)%3dO)O%5bC%40%5d1(%5bH%5d)C(%5bH%5d)(%5bH%5d)%5bC%40%5d(%5bH%5d)(%5bC%40%5d(%5bH%5d)(%5bC%40%40%5d(%5bH%5d)(C(%5bH%5d)(%5bH%5d)%5bH%5d)O1)OC(%5bH%5d)(%5bH%5d)%5bH%5d)O%5bH%5d)O%5bH%5d)O%5bH%5d)%3dO)O%5bH%5d)O%5bH%5d)
C%3d2)F)%3dO)%5bC%40H%5d1C1C%3dNC%3dCC%3d1)%3dO)(F)F)
%3dO)C(COC(CCCC%2fC%3dC%5cC%2fC%3dC%5cC%2fC%3dC%5cCCCCC)%3dO)COC(CCCC%2fC%3dC%5cC%2fC%3dC%5cC%2fC%3dC%5cCCCCC)%3dO)
O)O)C%2fC%3dC%5cCCC(%3dO)OC)